|1.||Zolotukhin, I A: 3 articles (01/2007 - 01/2006)|
|2.||Belcaro, G: 3 articles (04/2006 - 07/2002)|
|3.||Acerbi, G: 3 articles (04/2006 - 07/2002)|
|4.||Ricci, A: 3 articles (04/2006 - 07/2002)|
|5.||Dugall, M: 3 articles (04/2006 - 07/2002)|
|6.||Cesarone, M R: 3 articles (04/2006 - 07/2002)|
|7.||Ippolito, E: 3 articles (04/2006 - 07/2002)|
|8.||Silambarasan, Thangarasu: 2 articles (08/2014 - 03/2012)|
|9.||Raja, Boobalan: 2 articles (08/2014 - 03/2012)|
|10.||Tahir, Mir: 2 articles (07/2013 - 03/2013)|
06/01/1994 - "A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders."
11/01/2001 - "The aim of this study was to prospectively investigate the clinical efficacy of Daflon therapy in patients with mild to moderate chronic venous insufficiency (CVI) (clinical class 1-4) and to assess the changes in venous hemodynamics by using air plethysmography (APG). "
06/01/1994 - "The efficacy of Daflon 500 mg has been investigated in three double-blind, randomized trials using strain gauge plethysmography to provide quantitative information on venous hemodynamics in patients with chronic venous insufficiency. "
01/01/1997 - "[The chronobiology and clinical efficacy of Daflon in the treatment of chronic venous insufficiency]."
01/01/2006 - "The study was held to assess clinical effectiveness of coaggregated semisynthetic Diosmin (Phlebodia 600) for patients with II-III CEAP classes of chronic venous insufficiency (CVI), caused by lower limb variceal diseases. "
01/01/1997 - "Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients."
01/01/1997 - "To assess the efficacy of a micronized purified flavonoid fraction (Daflon 500 mg = Dios) in venous leg ulcer healing, in addition to compression therapy and standardized local care. "
09/01/2005 - "The objective of this study was to assess the effect of oral treatment with Daflon 500 mg (micronized purified flavonoid fraction [MPFF]) on leg ulcer healing. "
09/01/2005 - "Daflon 500 mg and venous leg ulcer: new results from a meta-analysis."
08/01/2001 - "In venous leg ulcer, Daflon 500 mg's clinical efficacy has been demonstrated in addition to standard treatment or versus standard treatment alone. "
08/01/2001 - "In edema, one of the most frequent complaints of patients, Daflon 500 mg brings about a significant reduction in leg circumference, thanks to its capacity to inhibit inflammatory reactions and to decrease capillary hyperpermeability. "
09/01/2005 - "The therapeutic efficacy of Daflon 500 mg on CVD symptoms and edema has been demonstrated in double-blind, randomized, controlled studies. "
09/01/2005 - "Daflon 500 mg (micronized purified flavonoid fraction [MPFF]) is an effective treatment for symptoms and edema in CVD as demonstrated in several randomized controlled studies. "
07/01/2003 - "Daflon 500 mg is thus the first-line treatment for edema and symptoms of CVI at any stage of the disease. "
07/01/2003 - "From symptoms to leg edema: efficacy of Daflon 500 mg."
04/01/2014 - "Both Roidosanal(®) and Daflon(®) 500 mg were equally effective in resolving signs and symptoms of hemorrhoids. "
06/01/1994 - "The author reports the results of a double-blind, placebo-controlled trial of the efficacy of Daflon 500 mg in the treatment of acute and chronic symptoms of hemorrhoids. "
12/01/2002 - "Efficacy of Daflon in the treatment of hemorrhoids."
04/01/2014 - "In this pilot, active controlled, open-labeled multicentre study, 73 patients with proctoscopy proven hemorrhoids (Grade I to III) were randomly assigned to receive either Roidosanal(®) (Gr R; n = 37) or Daflon(®) 500 mg (Gr D; n = 36), for 15 days, at three centers in India. "
12/01/2010 - "(Vitaceae) to Daflon (Servier) and placebo in the treatment of acute hemorrhoids."
01/01/2011 - "Diosmin ameliorates intestinal injury induced by hepatic ischemia reperfusion in rats."
08/05/2014 - "Objective of the current study is to evaluate the cardio-protective and antioxidant effect of diosmin on ischemia-reperfusion related cardiac dysfunction, oxidative stress and apoptosis. "
07/01/2003 - "The objective of this study was to investigate the effects of Daflon 500 mg on tissue damage in kidney after ischemia/reperfusion hindlimb, by assessing blood biochemical assay and histopathological analysis. "
08/05/2014 - "Diosmin pretreatment improves cardiac function and suppresses oxidative stress in rat heart after ischemia/reperfusion."
01/01/2013 - "Diosmin (100 mg/kg) or vehicle solution was administered intragastrically 30 min before the onset of ischemia and then daily after I/R injury until the animals were sacrificed. "
|5.||Plant Preparations (Preparation, Plant)
|6.||Proliferating Cell Nuclear Antigen (PCNA)
|7.||2-Acetylaminofluorene (2 Acetylaminofluorene)